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Abstract
Background: Nuclear receptor coactivator-3 (NCOA3) is involved in various physiological processes. Emerging
evidence from previous studies using animal models suggests that the NCOA3 gene (NCOA3) plays a critical role
in lipid metabolism as well as adipogenesis and obesity. The present study aims to investigate the association
between NCOA3 SNPs and dyslipidemia in the Chinese Han population.
Methods: Five hundred and twenty-nine (529) Chinese Han subjects were recruited. Four tag SNPs (rs2425955G > T,
rs6066394T > C, rs10485463C > G, and rs6094753G > A) in NCOA3, selected from the HapMap website, were
genotyped using MALDI-TOF mass spectrometry. Data analysis was performed using SPSS 16.0, SNPStats and
haploview 4.2.
Results: Four SNPs (rs2425955, rs6066394, rs10485463, and rs6094753) were associated with triglyceride levels.
Except for SNP rs10485463, genotype distributions and allele frequencies of the other three NCOA3 SNPs
(rs2425955, rs6066394, and rs6094753) were significantly different between hypertriglyceridemia subjects and
normal group. Significant differences were also observed in allele frequencies and genotype distributions of SNP
rs10485463 between low-HDL cholesterolemia subjects and normal group. Carriers of rs2425955 T allele had a
lower risk of hypertriglyceridemia compared to GG genotype. Similar results were observed from rs6094753.
Subjects with rs6066394 CT genotype had a lower risk of hypertriglyceridemia than those with the TT genotype;
however, CC and TT genotypes showed no significant difference in the risk of hypertriglyceridemia. Similar results
were found in the association between rs6066394 and hypercholesterolemia. The variant alleles of rs2425955,
rs6066394 and rs6094753 were associated with a lower risk of hypertriglyceridemia compared with the wild-type
alleles. The G allele of rs10485463 was associated with an increased risk of low-HDL cholesterolemia. In the log-additive
model the association between rs2425955 and hypertriglyceridemia remained significant after Bonferroni correction,
and genotypes with variant alleles were associated with a lower risk of hypertriglyceridemia.
Conclusions: In summary, this study demonstrated that variation in NCOA3 might influence the risk of dyslipidemia
and serum lipid levels in Chinese Han population.
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Background
Nuclear receptor coactivator-3 (NCOA3), a member of
the p160 family of nuclear receptor coactivators, plays
significant roles in various physiological processes, such
as mammary gland development, cell reproduction,
somatic growth, and female generative function [1].
NCOA3 gene, consisting of 22 exons, is located in
chromosomal region 20q12 and its mRNA was ex-
pressed in various tissues, such as muscle, heart, liver,
brain, mammary gland [2–7].
Previous studies provided evidence that the NCOA3
gene (NCOA3) plays a primary role in adipogenesis as
well as obesity by regulating the gene expression of per-
oxisome proliferator-activated receptor γ (PPARγ) - the
master regulator of adipocyte development and differen-
tiation [8–16]. These studies demonstrated that NCOA3
could enhance the transcriptional activity of PPARγ
which promotes obesity, and that adipocyte differentiation
was suppressed in NCOA3 knockout mice with a signifi-
cantly decreased gene expression of PPARγ [8–11]. Be-
sides, the researchers found that NCOA3 deficient mice
redistributed fat between visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SCAT) under high-fat
diet (HFD), and that NCOA3 ablation led to a significantly
higher VAT/SCAT weight ratio under HFD versus normal
diet - providing an evidence of the role in redistributing
fat distribution for NCOA3 [17]. Studies also revealed
that obese people with VAT fat accumulation were
more tightly related to the risk of suffering from
diabetes mellitus and dyslipidemia than those with a
normal fat distribution [18, 19].
In addition to its crucial role in controlling adipogene-
sis and fat distribution, emerging evidence from meta-
bolic studies [20–22] has shown that NCOA3 can
participated in metabolic control and energy homeosta-
sis. Ma et al. [20] reported that deletion of NCOA3 ame-
liorated hepatic steatosis and lipid accumulation in mice
fed with a high-fat diet. Thus, NCOA3 plays a critical
role in regulating hepatic lipid metabolism. A study by
Coste et al. [22] demonstrated that caloric excess
induced NCOA3 expression, leading to the restraint of
activity of PPARγ coactivator-1α (PGC-1α, which is the
coordinator of mitochondrial function) and decreased
energy expenditure (EE), while caloric restriction re-
duced NCOA3 levels, resulting in improved PGC-1α ac-
tivity, increased EE and an improved metabolic profile,
such as lower fasting cholesterol, triglycerides, and free
fatty acids levels. Disturbance in energy homeostasis,
which is sustained by a balance between energy intake
and energy expenditure, may lead to metabolic diseases
such as obesity, dyslipidemia, and atherosclerosis [23].
Dyslipidemia is a significant risk factors for coronary
heart disease, which is a major public health problem in
the worldwide. Although the exact cause of dyslipidemia
is unknown, blood lipid level is influenced by multiple
genetic and environmental factors and their interactions
[24, 25]. It is clear from the published literature that
NCOA3 plays a critical role in adipogenesis, energy
homeostasis, and lipid metabolism. However, to the best
of our knowledge, studies on NCOA3 gene so far are
carried out mainly on animal models, with no published
epidemiologic studies that investigated the association of
human NCOA3 single nucleotide polymorphisms (SNPs)
and metabolic disorders. In this study, we intended to
analyze the association between polymorphisms of hu-
man NCOA3 and dyslipidemia.
Results
47.6 % of the respondents were males, with an average
age of 58 ± 10 years. The percentages of subjects with
hypertriglyceridemia, hypercholesterolemia, low-HDL
cholesterolemia, and hyper-LDL cholesterolemia were
30.6, 18.7, 15.9, and 30.1 %, respectively. Table 1 shows
the average plasma level of lipids.
The four SNPs were significantly associated with
plasma levels of triglyceride (P = 0.009, 0.004, 0.019, and
0.006, respectively), and subjects carrying the variant
allele of the four SNPs had a lower level of triglyceride
than those who were homozygous for the wild-type
allele. However, the significant association between these
four SNPs and three other serum lipid parameters (TC,
LDL and HDL) were not observed (Table 2).
The genotype distributions of the four NCOA3 SNPs
in the normal group conformed to Hardy–Wein-
berg equilibrium (HWE) (data not shown). Allele fre-
quencies and genotype distributions of the four SNPs in
NCOA3 are presented in Table 3. Except for SNP
rs10485463, genotype distributions and allele frequencies
of the other three NCOA3 SNPs (rs2425955, rs6066394,
and rs6094753) were significantly different between
hypertriglyceridemia subjects and normal group. Signifi-
cant differences were also observed in allele frequencies
Table 1 Characteristics of study subjects
Characteristics Men Women Total
(n = 252) (n = 277) (n = 529)
Age, years 58 ± 10 60 ± 9 59 ± 10
Hypertriglyceridemia, n (%) 85(33.7) 77(27.8) 162(30.6)
Hypercholesterolemia, n (%) 38(15.1) 61(22.0) 99(18.7)
High LDL, n (%) 30(11.9) 54(19.5) 84(15.9)
Reduced HDL, n (%) 101(40.1) 58(20.9) 159(30.1)
TG, mmol/l 2.28 ± 2.36 2.07 ± 1.91 2.17 ± 2.14
TC, mmol/l 5.08 ± 1.06 5.32 ± 1.18 5.21 ± 1.13
LDL, mmol/l 3.02 ± 0.99 3.28 ± 1.03 3.16 ± 1.02
HDL, mmol/l 1.23 ± 0.44 1.35 ± 0.42 1.30 ± 0.43
Means ± standard deviation for age, TG, TC, LDL, and HDL
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and genotype distributions of SNP rs10485463 between
low-HDL cholesterolemia subjects and normal group.
Logistic regression analysis revealed that hypertri-
glyceridemia was associated with three NCOA3 SNPs
(rs2425955, rs6066394, and rs6094753). Subjects carrying
the variant allele of SNP rs2425955 (genotypes: GT and
TT) had a lower risk of developing hypertriglyceridemia
compared to those who were homozygous for the wild-
type allele G (GT vs. GG: OR = 0.60, 95 % CI = 0.40–0.89;
TT vs. GG: OR = 0.34, 95 % CI = 0.14–0.86). Similar
results were obtained from SNP rs6094753 (GA vs. GG:
OR = 0.62, 95 % CI = 0.41–0.92; AA vs. GG: OR = 0.37,
95 % CI = 0.15–0.94). Subjects with the CT genotype of
rs6066394 had a lower risk of hypertriglyceridemia than
those with the TT genotype (OR = 0.55, 95 % CI =
0.37–0.83); but those with the CC and TT genotypes
showed no significant differences in the risk of suffering
from hypertriglyceridemia (OR = 0.70, 95 % CI = 0.38–1.27).
Besides, the CT genotype of rs6066394 was slightly associ-
ated with a lower risk of hypercholesterolemia compared
to the TT genotype (OR = 0.61, 95 % CI = 0.37–1.00).
Similarly, the CC and TT genotypes of rs6066394 showed
no significant differences in the risk of developing hyper-
cholesterolemia (OR = 0.70, 95 % CI = 0.34–1.44). The GG
genotype of SNP rs10485463 was associated with low-
HDL cholesterolemia in comparison to the CC genotype
(OR = 2.27, 95 % CI = 1.12–4.61); however, there was no
significant difference between the CG and CC genotypes
in affecting HDL levels (OR = 1.28, 95 % CI = 0.83–1.97).
In addition, we explored the association of the allele of
the four SNPs with dyslipidemia. As shown in Table 4,
the variant alleles of rs2425955 and rs6094753 were as-
sociated with a lower risk of hypertriglyceridemia com-
pared with the wild-type alleles of these two SNPs
(rs2425955: OR = 0.61, 95 % CI = 0.44–0.83; rs6094753:
OR = 0.62, 95 % CI = 0.45–0.86). The C allele of SNP
rs6066394 was significantly associated with a lower risk
of hypertriglyceridemia (OR = 0.73, 95 % CI = 0.54–0.97).
Compared with the C allele of SNP rs10485463, the G
allele of SNP rs10485463 was associated with low-HDL
cholesterolemia (OR = 1.48, 95 % CI = 1.09–2.00).
The association of NCOA3 polymorphisms and dyslipid-
emia was further investigated through inheritance models.
Only rs2425955 was significantly associated with hyper-
triglyceridemia after Bonferroni correction (P = 0.0010)
(Table 5), and subjects with the variant allele had a lower
risk of developing hypertriglyceridemia (OR = 0.59, 95 %
CI = 0.43–0.82). However, no significant association
between the four SNPs and dyslipidemia (hypercholes-
terolemia, low-HDL cholesterolemia, and hyper-LDL cho-
lesterolemia) was observed in any inheritance models
(data not shown).
Figure 1 displays the linkage disequilibrium (LD) of
the 4 SNPs in NCOA3. Except rs10485463, three other
SNPs were in close LD (D’ ≥ 0.97, r2 ≥ 0.63).
Discussion
In this study, our findings indicated that variation in
NCOA3 might influence the risk of dyslipidemia and
serum lipid levels in Chinese Han population.
Previous studies have now convincingly demonstrated
that the NCOA3 gene plays a critical role in adipogenesis
Table 2 The association between NCOA3 polymorphisms and serum lipid
SNP Genotype TC(mmol/l) LDL(mmol/l) TG(mmol/l) HDL(mmol/l)
rs10485463 CC(n = 247) 5.2 ± 1.2 3.1 ± 0.9 2.3 ± 2.2 1.3 ± 0.4
CG(n = 193) 5.1 ± 1.2 3.1 ± 1.0 2.1 ± 2.2 1.3 ± 0.4
GG(n = 40) 5.1 ± 1.1 3.2 ± 0.9 1.6 ± 0.9 1.2 ± 0.4
P 0.669 0.795 0.009 0.056
rs2425955 GG(n = 269) 5.4 ± 1.1 3.2 ± 1.1 2.4 ± 3.1 1.3 ± 0.4
GT(n = 206) 5.1 ± 1.1 3.1 ± 0.9 1.9 ± 1.8 1.3 ± 0.4
TT(n = 36) 4.9 ± 1.0 3.0 ± 0.8 1.5 ± 0.8 1.3 ± 0.4
P 0.051 0.707 0.004 0.801
rs6066394 CC(n = 65) 5.1 ± 1.3 3.1 ± 0.8 2.5 ± 3.0 1.3 ± 0.3
CT(n = 223) 5.1 ± 1.0 3.1 ± 0.9 2.1 ± 2.5 1.3 ± 0.4
TT(n = 217) 5.3 ± 1.2 3.2 ± 1.1 1.9 ± 1.8 1.3 ± 0.4
P 0.070 0.590 0.019 0.581
rs6094753 GG(n = 283) 5.3 ± 1.1 3.2 ± 1.1 2.9 ± 3.8 1.3 ± 0.4
GA(n = 201) 5.1 ± 1.1 3.1 ± 0.9 2.4 ± 2.4 1.3 ± 0.4
AA(n = 35) 5.0 ± 1.1 3.2 ± 0.9 1.9 ± 1.7 1.2 ± 0.4
P 0.101 0.682 0.006 0.444
Data was represented as mean ± SD, and P value was calculated with the general linear model adjusted for age and sex
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by controlling the expression of PPARγ gene which is the
master regulator of adipocyte development and differenti-
ation [8–16]. In animal models, NCOA3 ablation leads to
reduced body weight and adipocyte volume due to
impaired white adipocyte differentiation, and a significant
decrease in the expression of PPARγ, while re-expression
of NCOA3 restored the adipocyte differentiation program.
During adipocyte differentiation, NCOA3 served as
Table 3 Genotype distributions and allele frequencies in dyslipidemia and normal groups
SNPs Hypercholesterolemia Normal group Hypertriglyceridemia Normal group High LDL Normal group Reduced HDL Normal group
rs10485463
CC 48(53.9) 199(50.9) 87(57.6) 160(48.6) 35(49.3) 212(51.8) 61(44.5) 186(54.2)
CG 33(37.1) 160(40.9) 54(35.8) 139(42.2) 30(42.3) 163(39.9) 58(42.3) 135(39.4)
GG 8(9.0) 32(8.2) 10(6.6) 30(9.1) 6(8.5) 34(8.3) 18(13.1) 22(6.4)
χ2 0.452 3.48 0.164 7.319
P 0.798 0.175 0.921 0.026
C 129(72.5) 558(71.4) 228(75.5) 459(69.8) 100(70.4) 587(71.8) 180(65.7) 507(73.9)
G 49(27.5) 224(28.6) 74(24.5) 199(30.2) 42(29.6) 231(28.2) 94(34.3) 179(26.1)
χ2 0.089 3.351 0.106 6.49
P 0.766 0.067 0.744 0.011
rs2425955
GG 57(60.0) 212(51.0) 99(62.3) 170(48.3) 42(52.5) 227(52.7) 81(54.4) 188(51.9)
GT 34(35.8) 172(41.3) 54(34.0) 152(43.2) 35(43.8) 171(39.7) 58(38.9) 148(40.9)
TT 4(4.2) 32(7.7) 6(3.8) 30(8.5) 3(3.8) 33(7.7) 10(6.7) 26(7.2)
χ2 3.123 9.876 1.740 0.252
P 0.210 0.007 0.419 0.882
G 148(77.9) 596(71.6) 252(79.2) 492(69.9) 119(74.4) 625(72.5) 220(73.8) 534(72.4)
T 42(22.1) 236(28.4) 66(20.8) 212(30.1) 41(25.6) 237(27.5) 78(26.2) 200(27.6)
χ2 3.061 9.689 0.238 0.224
P 0.080 0.002 0.626 0.636
rs6066394
TT 49(52.7) 168(40.8) 81(51.9) 138(39.0) 36(45.6) 181(42.5) 67(45.6) 150(41.9)
CT 33(35.5) 190(46.1) 56(35.9) 167(47.9) 35(44.3) 188(44.1) 63(42.9) 160(44.7)
CC 11(11.8) 54(13.1) 19(12.2) 46(13.2) 8(10.1) 57(13.4) 17(11.6) 48(13.4)
χ2 4.554 7.783 0.696 0.683
P 0.103 0.020 0.706 0.711
T 131(70.4) 526(63.8) 218(69.9) 443(63.1) 107(67.7) 550(64.6) 197(67.0) 460(64.2)
C 55(29.6) 298(36.2) 94(30.1) 259(36.9) 51(32.3) 302(35.4) 97(33.0) 256(35.8)
χ2 2.903 4.618 0.588 0.699
P 0.088 0.032 0.443 0.403
rs6094753
GG 60(61.9) 223(52.8) 101(63.5) 182(50.6) 44(53.7) 239(54.7) 86(55.5) 197(54.1)
GA 30(30.9) 171(40.5) 52(32.7) 149(41.4) 32(39.0) 169(38.7) 56(36.1) 145(39.8)
AA 7(7.2) 28(6.6) 6(3.8) 29(8.1) 6(7.3) 29(6.6) 13(8.4) 22(6.0)
χ2 3.089 8.547 0.063 1.308
P 0.213 0.014 0.969 0.520
G 150(77.3) 617(73.1) 254(79.9) 513(71.2) 120(73.2) 647(74.0) 228(73.5) 539(74.0)
A 44(22.7) 227(26.9) 64(20.1) 207(28.8) 44(26.8) 227(26.0) 82(26.5) 189(26.0)
χ2 1.453 8.504 0.053 0.027
P 0.228 0.004 0.819 0.869
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coactivator that synergistically facilitates the gene expres-
sion of PPARγ with specific transcriptional factors of the
CCAAT/enhancer-binding proteins(C/EBP) [8, 9].
PPARγ, a member of the nuclear hormone receptors
that can interacts with its binding partner - retinoid X
receptor α, can bind to DNA within the promoter ele-
ments of target genes [26]. PPARγ, predominantly found
in adipose tissue and macrophages, functions as a regu-
lator for adipocyte differentiation, lipid storage, glucose
metabolism and play a vital role in the transcriptional
regulation of a number of genes involved in metabolism,
such as endothelial lipoprotein lipase (LPL), fatty acid
translocase (FAT) and uncoupling protein (UCP) [26, 27].
In the regulation of lipid metabolism, PPARγ enhances
plasmatic TG-rich liproprotein hydrolysis through directly
regulating the expression of LPL and promotes uptake of
fatty acid into adipocytes by controlling the expression of
FAT, also called CD36 in macrophages [28, 29]. Hence,
PPARγ promotes fat storage and reduces plasma lipid
levels, especially plasma levels of triglyceride.
Hence, the diverse biological functions of PPARγ, such
as regulation in lipid metabolism, lipid storage and so
on, might be influenced by the NCOA3 gene through
controlling PPARγ gene expression. And it can be further
concluded that the NCOA3 gene might have association
with plasma lipid levels and dyslipidemia, especially with
hypertriglyceridemia.
In the present study, our data showed that four NCOA3
SNPs were associated with plasma levels of triglyceride,
and except rs10485436, three other SNPs of NCOA3 gene
were associated with a decreased risk of hypertriglyc-
eridemia. In the further inheritance model analysis, only
rs2425955 was significantly associated with hypertriglyc-
eridemia after Bonferroni correction.
SNP rs2425955 is in linkage disequilibrium (LD) with
rs2076546 (D’ = 1) based on the Chinese HapMap data.
SNP rs2076546 is in the coding region of NCOA3 gene.
Although rs2076546 is a synonymous SNP and causes
no change from threonine [30], the study of Burwinkel
et al. [31] showed that polymorphism rs2076546
Table 4 Odds ratios for the likelihood of dyslipidemia according to NCOA3 polymorphisms
SNPs Hypercholesterolemia Hypertriglyceridemia High LDL Reduced HDL
OR(95 % CI) ORa(95 % CI) OR(95 % CI) ORa(95 % CI) OR(95 % CI) ORa(95 % CI) OR(95 % CI) ORa(95 % CI)
rs10485463
CC 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CG 0.85(0.52–1.39) 0.87(0.53–1.42) 0.71(0.47–1.07) 0.70(0.47–1.06) 1.11(0.66–1.89) 1.15(0.67–1.96) 1.31(0.86–2.00) 1.28(0.83–1.97)
GG 1.04(0.45–2.39) 1.09(0.47–2.54) 0.61(0.29–1.31) 0.57(0.26–1.23) 1.07(0.42–2.73) 1.19(0.46–3.07) 2.49(1.25–4.96) 2.27(1.12–4.61)
C 1.00 1.00 1.00 1.00
G 0.95(0.66–1.36) 0.75(0.55–1.02) 1.07(0.72–1.58) 1.48(1.09–2.00)
rs2425955
GG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
GT 0.73(0.46–1.18) 0.75(0.47–1.20) 0.61(0.41–0.91) 0.60(0.40–0.89) 1.11(0.68–1.81) 1.14(0.70–1.87) 0.91(0.61–1.36) 0.87(0.57–1.31)
TT 0.46(0.16–1.37) 0.46(0.16–1.36) 0.34(0.14–0.85) 0.34(0.14–0.86) 0.49(0.14–1.68) 0.49(0.14–1.67) 0.89(0.41–1.94) 0.89(0.40–1.97)
G 1.00 1.00 1.00 1.00
T 0.72(0.49–1.04) 0.61(0.44–0.83) 0.91(0.62–1.33) 0.93(0.68–1.26)
rs6066394
TT 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CT 0.59(0.37–0.97) 0.61(0.37–1.00) 0.56(0.37–0.85) 0.55(0.37–0.83) 0.94(0.56–1.56) 0.97(0.58–1.62) 0.88(0.58–1.33) 0.83(0.54–1.26)
CC 0.70(0.34–1.44) 0.70(0.34–1.44) 0.69(0.38–1.26) 0.70(0.38–1.27) 0.71(0.31–1.60) 0.70(0.31–1.60) 0.79(0.42–1.48) 0.79(0.42–1.50)
T 1.00 1.00 1.00 1.00
C 0.74(0.52–1.05) 0.73(0.54–0.97) 0.87(0.60–1.25) 0.88(0.66–1.18)
rs6094753
GG 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
GA 0.65(0.40–1.05) 0.66(0.41–1.07) 0.63(0.42–0.94) 0.62(0.41–0.92) 1.03(0.63–1.69) 1.06(0.64–1.74) 0.88(0.59–1.32) 0.84(0.56–1.26)
AA 0.93(0.39–2.23) 0.92(0.38–2.21) 0.37(0.15–0.93) 0.37(0.15–0.94) 1.12(0.44–2.86) 1.11(0.43–2.85) 1.35(0.65–2.81) 1.42(0.67–3.00)
G 1.00 1.00 1.00 1.00
A 0.80(0.55–1.15) 0.62(0.45–0.86) 1.04(0.72–1.52) 1.03(0.76–1.39)
aORs and 95 % CI were adjusted for age and sex
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provoked a shift to less preferred codon ACG from the
more preferred codon ACA in NCOA3 gene. The
altered codon usage may decrease NCOA3 gene tran-
scriptional and/or translational level [31–34]. Previous
studies reported that NCOA3 facilitates PPARγ gene
expression [8,9], and PPARγ promotes fat storage and
reduces plasma lipid levels, especially plasma levels of
triglyceride [28,29]. We hypothesize that decrease in
transcription and translation of NCOA3 caused by poly-
morphism rs2076546 may lead to decrease in PPARγ ex-
pression level which may lead to increase in the plasma
levels of triglyceride and hypertriglyceridemia. Hence,
the association of rs2425955 with hypertriglyceridemia
might be explained by the effect of rs2076548 which is
in LD with rs2425955.
In addition, rs2425955 is located at the intron 1 of
NCOA3. Hsia et al. found several functional E2F binding
sites in the intron 1 and exon 1 of NCOA3 gene which
were crucial for NCOA3 gene activation [35]. E2Fs,
coactivated by NCOA3, is a transcription factor family
that regulates genes expression in cell cycle progression
and DNA synthesis [35–38]. Their data showed that
these functional binding sites in the intron 1 may
influence E2F activation, and enhanced activation of E2F
could at least in part increase the expression of NCOA3
gene [35]. Previous studies reported that gene polymor-
phisms may regulate gene expression by changing the
binding sites of transcription factors, and may further be
associated with specific phenotypes [39,40]. We suppose
that intron 1 SNPs of NCOA3 may have potential effect
on gene transcription. Based on the consideration, we
intended to indentify putative E2F binding sites in intron
1 using the JASPAR database [41], and found that there
was a putative binding site sequence (CGCGCCCCAGC)
near the rs2425955. SNP rs2425955 was 36 bp away from
the putative binding site. We suppose that polymorphism
rs2425955 may influence steric conformation of chromo-
some region which contains the putative binding site
or the two functional binding sites, and further have
potential effect on transcription factor binding, which
may influence gene transcription, expression and its
biological function. However, functional studies are
needed to clarify the potential role of intron 1 SNPs,
especially rs2425955, on NCOA3 gene transcription
and expression.
The reasons mentioned above may explain the asso-
ciation between rs2425955 and hypertriglyceridemia in
our study. There is scarcely any information about the
relationship between NCOA3 SNPs and dyslipidemia
in humans. Our sample size is relatively small, replica-
tion of the finding from this study with a larger sam-
ple is necessary to further explore the role of the
target gene and its variation in the development of
metabolic disorders.
Table 5 The association of NCOA3 SNPs with Hypertriglyceridemia
risk in inheritance models
SNPs Model Genotype ORa(95 % CI) P
rs10485463 Codominant CC 1.00 0.1300
CG 0.70(0.47–1.06)
GG 0.57(0.26–1.23)
Dominant CC 1.00 0.0500
CG + GG 0.68(0.46–1.00)
Recessive CC + CG 1.00 0.2700
GG 0.66(0.31–1.40)
Overdominant CC + GG 1.00 0.0450
CG 0.76(0.51–1.13)
log-additive 0.73(0.53–1.00)
rs2425955 Codominant GG 1.00 0.0048
GT 0.60(0.40–0.89)
TT 0.34(0.14–0.85)
Dominant GG 1.00 0.0025
GT + TT 0.56(0.38–0.82)
Recessive GG + GT 1.00 0.0400
TT 0.42(0.17–1.03)
Overdominant GG + TT 1.00 0.0390
GT 0.66(0.45–0.98)
log-additive 0.59(0.43–0.82) 0.0010
rs6066394 Codominant TT 1.00 0.0170
TC 0.55(0.37–0.83)
CC 0.70(0.38–1.27)
Dominant TT 1.00 0.0057
TC + CC 0.58(0.40–0.86)
Recessive TT + TC 1.00 0.7900
CC 0.93(0.52–1.64)
Overdominant TT + CC 1.00 0.0094
TC 0.60(0.41–0.89)
log-additive 0.73(0.55–0.98) 0.0310
rs6094753 Codominant GG 1.00 0.0100
GA 0.62(0.41–0.92)
AA 0.37(0.15–0.93)
Dominant GG 1.00 0.0048
GA + AA 0.58(0.39–0.85)
Recessive GG + GA 1.00 0.0620
AA 0.45(0.18–1.11)
Overdominant GG + AA 1.00 0.0480
GA 0.68(0.46–1.00)
log-additive 0.61(0.44–0.85) 0.0025
aThe ORs and 95 % CI were adjusted for age and gender. P < 0.0025 was
considered statistically significant due to bonferroni corrected P-value = 0.0025
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Besides, SNP rs10485463 was associated with low-
HDL cholesterolemia, and SNP rs6066394 was slightly
associated with a lower risk of hypercholesterolemia in
our study. However, in the analysis of inheritance
models the association between the four SNPs and dys-
lipidemia (hypercholesterolemia and low-HDL cholester-
olemia) was not observed after bonferroni correction.
Therefore, whether the two SNPs (rs10485463 and
rs6066394) are associated with dyslipidemia needs to be
further studied.
Conclusions
The four NCOA3 SNPs were associated with plasma
levels of triglyceride, and except rs10485436, three other
SNPs of NCOA3 gene were associated with a decreased
risk of hypertriglyceridemia. In addition, SNP rs10485463
was associated with low-HDL cholesterolemia, and SNP
rs6066394 was slightly associated with a lower risk of
hypercholesterolemia. In conclusion, our present study
revealed that the polymorphisms in NCOA3 might be in




This study recruited participants from two sources, both
in Jilin Province, Northeast of China: from the General
Hospital of Jilin Chemical Group Corporation and from
a survey of the prevalence and risk factors of chronic
diseases among adults in Jilin. One hundred and ninety-
two (192) Chinese Han subjects were randomly selected
from individuals who received routine health examina-
tions at the General Hospital of Jilin Chemical Group
Corporation between September 2009 and June 2010.
Three hundred and thirty- seven (337) subjects were re-
cruited from a survey conducted in July 2012 on the
prevalence and risk factors of chronic diseases among
adults in Jilin Province. All study participants accepted
general health examination included blood pressure,
BMI, and plasma levels of lipids. A total of 529 (252
males and 277 females) subjects with an average age of
59 ± 10 years were included in this study. All subjects
were unrelated Chinese Han.
Dyslipidemia was assessed according to the Guide-
lines on Prevention and Treatment of dyslipidemia in
Chinese Adults [42]: hypertriglyceridemia: triglyceride
(TG) ≥2.26 mmol/L;hypercholesterolemia: total choles-
terol (TC) ≥6.22 mmol/L; Hyper-LDL cholesterolemia:
LDL-C ≥4.14 mmol/L; Low-HDL cholesterolemia:
HDL-C < 1.04 mmol/L.
The study was approved by the ethics committee of
the School of Public Health, Jilin University, and in-
formed consents were provided by all subjects.
Tag SNP selection
NCOA3 gene is located in chromosomal region 20q12.
Tag SNPs for NCOA3 were chosen from the HapMap
database (HapMap Genome Brower release # 24) [43].
In the public HapMap database (phase II Nov08, on
NCBI B36 assembly, dbSNP b126) tag SNPs were
Fig. 1 Linkage disequilibrium structure and relative chromosomal positions of the four SNPs. a Linkage disequilibrium plot showing D’ multiplying
100; (b) Linkage disequilibrium plot showing r2 multiplying 100
Yu et al. Lipids in Health and Disease  (2015) 14:124 Page 7 of 9
selected under the following options: Han Chinese in
Beijing population (CHB), r2 cut-off of 0.8, tagger
pairwise as pairwise methods and MAF cut-off of 10 %.
Four tag SNPs (rs2425955 G > T, rs6066394 T > C,
rs10485463 C > G, and rs6094753 G > A) of NCOA3
were chosen. The positions of rs2425955, rs6066394,
rs10485463, and rs6094753 are intron 1, intron 1, intron 2,
and intron 8 of the NCOA3 gene respectively.
DNA extraction, purification, and SNP genotyping
Genomic DNA was extracted from peripheral blood
samples using standard protocol (phenol/chloroform ex-
traction), and the quality and quantity were determined
by spectrophotometry.
Genotyping was conducted by polymerase chain reac-
tion (PCR) and MALDI-TOF mass spectrometry [44]
using the MassARRAY iPLEX System (Sequenom Inc.,
San Diego, CA).
Data analysis
Clinical and biochemical data were expressed as mean ± SD
or percentage. One sample Kolmogorov-Smirnov test was
applied to evaluate whether TG, TC, LDL, and HDL were
in normal distributions. Two variables, TG and HDL, were
logarithmically transformed to conform to normality in
order to allow covariance analysis. The association be-
tween the four NCOA3 SNPs and quantitative clinical
traits was assessed by covariance analysis. The goodness
of fit Chi-square test was used to check if genotype distri-
butions were in HWE. The Chi-square test was used to
check if allele frequencies and genotype distributions were
significantly different between dyslipidemia group and
normal group. The associations between the allele of the
four SNPs of NCOA3 and dyslipidemia were evaluated by
odds ratios and their 95 % confidence intervals (CI) using
Chi-square test. Logistic regression analysis was used to
detect associations between genotypes of NCOA3 SNPs
and dyslipidemia. When we explored the association
using logistic regression without any adjustment, we set
hypercholesterolemia, hypertriglyceridemia, low-HDL
cholesterolemia, and hyper-LDL cholesterolemia as the
dependent variables, and genotypes as independent vari-
able. When we explored the association after adjust-
ment for age and sex, we set hypercholesterolemia,
hypertriglyceridemia, low-HDL cholesterolemia, and
hyper-LDL cholesterolemia as the dependent variable,
genotypes, sex, and age (continuous) as independent
variable, and enter as method. The strength of any evident
association was explored by calculating odds ratios to-
gether with their 95 % CI. Besides, the association between
the four NCOA3 SNPs and dyslipidemia in five inherit-
ance models (codominant, dominant, recessive, overdomi-
nant, and additive model) was analyzed using SNPstats
programs [45]. To reduce Type I error generated from the
association analysis involving four SNPs in the five genetic
models, bonferroni correction was applied to P values
for correcting multiple testing (corrected P-value:
0.05/(4 SNPs × 5 different genetic models) = 0.0025).
LD blocks of SNPs were constructed using SNP geno-
typing data in this study, and estimation of LD of 4
SNPs in NCOA3 (D’ and r2 represent the degree of
LD) was analyzed by haploview 4.2 software. The
power of this study was evaluated by Power and
Sample Size software version 3.1.2 [46, 47], and we
found that our study had a 0.745 power to detect a
significant difference between genotypes. All analyses
were performed using SPSS 16.0 for Windows unless
otherwise specified, and P-value <0.05 was considered
statistically significant.
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